Guardant Health vs Labcorp
GH and LH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GH and LH compare
Labcorp is the larger company, worth 1.2 times as much as Guardant Health ($29.9B against $24.0B).
Guardant Health grew revenue faster over the last twelve months (42.7% versus 6.0% for Labcorp).
Labcorp keeps more of each dollar of sales as profit, with a net margin of 6.9% compared with −38.3% at Guardant Health.
Labcorp pays a dividend yielding 0.78%; Guardant Health does not pay one.
Labcorp scores higher on the StockData Score (11 against 9 for Guardant Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GH | LH |
|---|---|---|
| Size and price | ||
| Market cap | $24.0B | $29.9B |
| Share price | $178.80 | $368.16 |
| Change, 1 year | 147% | 41.8% |
| Change, 5 years | 62.3% | 34.0% |
| Beta (5Y) | 1.61 | 0.61 |
| Employees | 2,506 | 71K |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 30.2× |
| P/S | 20.3× | 2.0× (better) |
| P/B | – | 3.4× |
| EV/EBITDA | – | 16.0× |
| P/FCF | – | 23.2× |
| FCF yield | −1.0% | 4.3% (better) |
| Fair value | – | $356.26 |
| Margin of safety | – | −3.3% |
| Growth | ||
| Revenue growth (TTM) | 42.7% (better) | 6.0% |
| Revenue growth, 5Y average | 27.9% (better) | −0.04% |
| Net income growth (TTM) | – | 17.4% |
| EPS growth (TTM) | – | 19.6% |
| EPS growth, 5Y average | – | −8.0% |
| Profitability | ||
| Gross margin | 65.0% (better) | 29.0% |
| Operating margin | −39.7% | 10.3% (better) |
| Net margin | −38.3% | 6.9% (better) |
| FCF margin | −20.3% | 8.8% (better) |
| Return on equity | – | 11.4% |
| Return on invested capital | – | 8.6% |
| Financial health | ||
| Debt / equity | – | 0.66 |
| Net debt / EBITDA | – | 2.53 |
| Interest coverage | −97.6× | 6.5× (better) |
| Current ratio | 4.03 (better) | 1.41 |
| Altman Z-score | 4.83 (better) | 3.55 |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.78% |
| Payout ratio | – | 23.6% |
| Years of dividend growth | – | 0 |
| Buyback yield | 0.00% | 2.3% (better) |
| Shareholder yield | 0.00% | 3.0% (better) |
| Ownership | ||
| Held by institutions | 99.8% | 98.0% |
| Held by insiders | 1.9% | 0.40% |
| Insider net buying, 12 months | −$174M | −$11.9M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 9.1% | 3.3% |
Go deeper
- GH stock overview
- GH income statement
- GH valuation and score
- LH stock overview
- LH income statement
- LH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.